Menadiol
Active ingredient
- Drug class
- -
- Availability
- See label
- Markets covered
- 1
- Products on record
- 1
Overview
Menadiol is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | November 28, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
For the treatment of haemorrhage or threatened haemorrhage associated with a low blood level of prothrombin or factor vii. The main indication is obstructive jaundice (before and after surgery). 1 Posology and method of administration Menadiol Diphosphate 10mg Tablets are for oral administration.
Adults Usual therapeutic dose: 10-40mg daily Children If, on the recommendation of a physician, a children's dosage is required, it is suggested that 5-20mg daily be given. The elderly Recommendations for use in the elderly do not differ from those for other adults.
Side effects & warnings
Sources & citations
- [1]MHRA (UK) · PL168530110 · revised November 28, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.